VVP
TGTX icon

Venture Visionary Partners’s TG Therapeutics TGTX Stock Holding History

Venture Visionary Partners’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-300
Closed -$1.27K – 1432
2022
Q2 		$1.27K Buy
+300
New +$1.87K ﹤0.01% 1580

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Venture Visionary Partners's TGTX Position: Q3 2022 in Review

Venture Visionary Partners sold out of TG Therapeutics (TGTX) in Q3 2022, closing a stake of 300 shares — an estimated $1.27K sold.

Venture Visionary Partners first reported a position in TGTX in Q2 2022 and held it in 1 quarter. The position peaked at $1.27K in Q2 2022. 183 funds tracked by Wall St. Rank hold TGTX as of Q3 2022.

  • Venture Visionary Partners reported no remaining TG Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Venture Visionary Partners sold 300 TG Therapeutics shares in Q3 2022, an estimated $1.27K.
  • Venture Visionary Partners first reported a position in TG Therapeutics in Q2 2022 and held it in 1 quarter.
  • Venture Visionary Partners's TG Therapeutics position peaked at $1.27K in Q2 2022.
  • 183 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2022.

Based on Venture Visionary Partners's 13F filing for Q3 2022, filed 14 Nov 2022.